September 1, 2021
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

SymBio enters into a collaborative research agreement with theNational Cancer Centre Singapore on Epstein-Barr virus positive lymphoma
TOKYO, Japan, September 1, 2021 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo,"SymBio") today announced that it has entered a collaborative research agreement with the NationalCancer Centre Singapore (NCCS) to explore anti-tumor activity and the mechanism of brincidofovir(BCV) IV in Epstein-Barr virus (EBV)1 positive lymphoma.
“This study aims to clarify the mechanism of action of BCV against EBV positive lymphoma. Based onthe findings, we hope to conduct clinical trials for patients with malignant lymphoma who may benefit
from treatment using BCV.” said Dr. Jason Yongsheng Chan, Principal Investigator of the study,
Consultant in the Division of Medical Oncology, NCCS and Clinical Assistant Professor at Duke-NUS
Medical School.
Statement from Mr. Fuminori Yoshida, President and Chief Executive Officer of SymBio: “BCV has awide range of antiviral effects against dsDNA viruses and is expected to be effective against EBVrelated diseases. EB viruses found in tumors and their viral proteins have been shown to be associatedwith disease by acting on intracellular signals to promote cellular tumorigenesis. This study will
elucidate the mechanism of action of BCV against EB virus-positive lymphoma, toward thedevelopment of new therapies."[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125

1

(Note 1) Epstein-Barr virus (EBV)The EBV is one of the human herpesvirus types and firstly investigated in the Burkitt lymphoma inchild, prevalent mainly in Africa, in 1964 as the oncogenic virus. Infection with EBV in childhood isusually asymptomatic or mild disease. When infection with EBV occurs during adolescence, it causes
infectious mononucleosis accompanied by transient fever, sore throat or lymphadenopathy. The
causal relationship of EBV with some malignant lymphoma, nasopharyngeal cancer and so on has
been clarified.
About Anti-viral Drug Brincidofovir
Brincidofovir (BCV) is a lipid conjugate of cidofovir (CDV). CDV is an antiviral drug already approved
and marketed in the United States and the European Union, but unapproved in Japan. As BCV
exhibits not only higher anti-viral activity, but also a superior safety profile in comparison with CDV,
BCV is expected to be an effective treatment against a wide spectrum of dsDNA viruses such as
herpesviruses such as cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV) and BKvirus, papillomavirus. Moreover, BCV is an easy-to-use and novel highly active antimultiviral agent
that can reduce the risk of nephrotoxicity, which is a serious side effect of CDV.
SymBio entered into an exclusive global license agreement with Chimerix Inc. (Headquarters:Durham, NC, "Chimerix") for brincidofovir (BCV) on September 30, 2019. Under the terms of theagreement, Chimerix grants SymBio exclusive worldwide rights to develop, manufacture, andcommercialize BCV in all human indications, excluding the prevention and treatment of orthopox
infections (which includes smallpox and monkeypox).
About the National Cancer Centre Singapore
The National Cancer Centre Singapore (NCCS) provides a holistic and multi-disciplinary approach tocancer treatment and patient care. NCCS sees close to 65 per cent of Singapore’s public sector oncology
cases, and they are benefiting from the sub-specialization of NCCS’ clinical oncologists.
To deliver among the best in cancer treatment and care, NCCS’ clinicians work closely with scientists
who conduct robust, cutting-edge clinical and translational research programs which areinternationally recognized. NCCS strives to be a global leading cancer centre, and shares its expertiseand knowledge by offering training to local and overseas medical professionals.
For more information, please visit: www.nccs.com.sg

2About Chimerix
Chimerix is a development-stage biopharmaceutical company dedicated to accelerating theadvancement of innovative medicines that make a meaningful impact in the lives of patients livingwith cancer and other serious diseases. In June 2021, the U. S. Food and Drug Administration
granted approval of TEMBEXA® for the treatment of smallpox as a medical countermeasure.
Chimerix has two other advanced clinical-stage development programs, ONC201 and dociparstat
sodium (DSTAT). ONC201 is currently in a registrational clinical program for recurrent H3 K27Mmutant glioma and blinded independent central review is expected later in 2021. DSTAT is indevelopment as a potential first-line therapy in acute myeloid leukemia. For further information,please visit the Chimerix website, www.chimerix.com.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen
Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., calledSymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida).
The Company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to bea leading global specialty biopharmaceutical company dedicated to addressing underserved medicalneeds.

3